Application of current knowledge to the management of bleeding events during immune tolerance induction

Jorge Di Paola, L. Aledort, H. Britton, M. Carcao, E. Grabowski, J. Hutter, J. Journeycake, C. Kempton, C. Leissinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The development of inhibitors to factor VIII is the most serious adverse event associated with the treatment of haemophilia A, predisposing patients to uncontrollable haemorrhage, disability and premature death. Eradication of inhibitors via immune tolerance induction (ITI) is effective in the majority of patients, but may require months to years to achieve success. In the interim, the treatment and prevention of acute bleeding episodes are primary foci of care. Regrettably, there is a paucity of information regarding management of bleeding episodes in inhibitor patients undergoing tolerization. Until specific data from ongoing clinical trials are available to provide more guidance in this patient group, it is reasonable and useful to rely on the broader base of medical literature pertaining to patients not being tolerized to deduce strategies for controlling acute and perioperative bleeding episodes in inhibitor patients during ITI.

Original languageEnglish (US)
Pages (from-to)591-597
Number of pages7
JournalHaemophilia
Volume12
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

Knowledge Management
Immune Tolerance
Hemorrhage
Information Management
Premature Mortality
Factor VIII
Hemophilia A
Primary Health Care
Clinical Trials
Therapeutics

Keywords

  • Bypassing agents
  • Haemophilia
  • Immune tolerance induction
  • Inhibitor
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology

Cite this

Di Paola, J., Aledort, L., Britton, H., Carcao, M., Grabowski, E., Hutter, J., ... Leissinger, C. (2006). Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia, 12(6), 591-597. https://doi.org/10.1111/j.1365-2516.2006.01343.x

Application of current knowledge to the management of bleeding events during immune tolerance induction. / Di Paola, Jorge; Aledort, L.; Britton, H.; Carcao, M.; Grabowski, E.; Hutter, J.; Journeycake, J.; Kempton, C.; Leissinger, C.

In: Haemophilia, Vol. 12, No. 6, 11.2006, p. 591-597.

Research output: Contribution to journalArticle

Di Paola, J, Aledort, L, Britton, H, Carcao, M, Grabowski, E, Hutter, J, Journeycake, J, Kempton, C & Leissinger, C 2006, 'Application of current knowledge to the management of bleeding events during immune tolerance induction', Haemophilia, vol. 12, no. 6, pp. 591-597. https://doi.org/10.1111/j.1365-2516.2006.01343.x
Di Paola, Jorge ; Aledort, L. ; Britton, H. ; Carcao, M. ; Grabowski, E. ; Hutter, J. ; Journeycake, J. ; Kempton, C. ; Leissinger, C. / Application of current knowledge to the management of bleeding events during immune tolerance induction. In: Haemophilia. 2006 ; Vol. 12, No. 6. pp. 591-597.
@article{eddca1e1f7714c69ad0a976eae1aef27,
title = "Application of current knowledge to the management of bleeding events during immune tolerance induction",
abstract = "The development of inhibitors to factor VIII is the most serious adverse event associated with the treatment of haemophilia A, predisposing patients to uncontrollable haemorrhage, disability and premature death. Eradication of inhibitors via immune tolerance induction (ITI) is effective in the majority of patients, but may require months to years to achieve success. In the interim, the treatment and prevention of acute bleeding episodes are primary foci of care. Regrettably, there is a paucity of information regarding management of bleeding episodes in inhibitor patients undergoing tolerization. Until specific data from ongoing clinical trials are available to provide more guidance in this patient group, it is reasonable and useful to rely on the broader base of medical literature pertaining to patients not being tolerized to deduce strategies for controlling acute and perioperative bleeding episodes in inhibitor patients during ITI.",
keywords = "Bypassing agents, Haemophilia, Immune tolerance induction, Inhibitor, Prophylaxis",
author = "{Di Paola}, Jorge and L. Aledort and H. Britton and M. Carcao and E. Grabowski and J. Hutter and J. Journeycake and C. Kempton and C. Leissinger",
year = "2006",
month = "11",
doi = "10.1111/j.1365-2516.2006.01343.x",
language = "English (US)",
volume = "12",
pages = "591--597",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Application of current knowledge to the management of bleeding events during immune tolerance induction

AU - Di Paola, Jorge

AU - Aledort, L.

AU - Britton, H.

AU - Carcao, M.

AU - Grabowski, E.

AU - Hutter, J.

AU - Journeycake, J.

AU - Kempton, C.

AU - Leissinger, C.

PY - 2006/11

Y1 - 2006/11

N2 - The development of inhibitors to factor VIII is the most serious adverse event associated with the treatment of haemophilia A, predisposing patients to uncontrollable haemorrhage, disability and premature death. Eradication of inhibitors via immune tolerance induction (ITI) is effective in the majority of patients, but may require months to years to achieve success. In the interim, the treatment and prevention of acute bleeding episodes are primary foci of care. Regrettably, there is a paucity of information regarding management of bleeding episodes in inhibitor patients undergoing tolerization. Until specific data from ongoing clinical trials are available to provide more guidance in this patient group, it is reasonable and useful to rely on the broader base of medical literature pertaining to patients not being tolerized to deduce strategies for controlling acute and perioperative bleeding episodes in inhibitor patients during ITI.

AB - The development of inhibitors to factor VIII is the most serious adverse event associated with the treatment of haemophilia A, predisposing patients to uncontrollable haemorrhage, disability and premature death. Eradication of inhibitors via immune tolerance induction (ITI) is effective in the majority of patients, but may require months to years to achieve success. In the interim, the treatment and prevention of acute bleeding episodes are primary foci of care. Regrettably, there is a paucity of information regarding management of bleeding episodes in inhibitor patients undergoing tolerization. Until specific data from ongoing clinical trials are available to provide more guidance in this patient group, it is reasonable and useful to rely on the broader base of medical literature pertaining to patients not being tolerized to deduce strategies for controlling acute and perioperative bleeding episodes in inhibitor patients during ITI.

KW - Bypassing agents

KW - Haemophilia

KW - Immune tolerance induction

KW - Inhibitor

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=33750683343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750683343&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2006.01343.x

DO - 10.1111/j.1365-2516.2006.01343.x

M3 - Article

C2 - 17083508

AN - SCOPUS:33750683343

VL - 12

SP - 591

EP - 597

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -